List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1968716/publications.pdf Version: 2024-02-01

		3325	277
329	89,636	91	295
papers	citations	h-index	g-index
335	335	335	78812
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. New England Journal of Medicine, 2004, 351, 1296-1305.	13.9	9,843
2	Heart Disease and Stroke Statistics—2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
3	Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA - Journal of the American Medical Association, 2001, 285, 2370.	3.8	5,547
4	Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, e38-360.	1.6	5,447
5	Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
6	Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, e6-e245.	1.6	4,387
7	Heart Disease and Stroke Statistics—2011 Update. Circulation, 2011, 123, e18-e209.	1.6	4,379
8	Heart Disease and Stroke Statistics—2012 Update. Circulation, 2012, 125, e2-e220.	1.6	4,096
9	Heart Disease and Stroke Statistics—2010 Update. Circulation, 2010, 121, e46-e215.	1.6	4,053
10	Heart Disease and Stroke Statistics—2008 Update. Circulation, 2008, 117, e25-146.	1.6	2,876
11	Heart Disease and Stroke Statistics—2007 Update. Circulation, 2007, 115, e69-171.	1.6	2,686
12	Executive Summary: Heart Disease and Stroke Statistics—2016 Update. Circulation, 2016, 133, 447-454.	1.6	2,093
13	Heart Disease and Stroke Statistics—2009 Update. Circulation, 2009, 119, e21-181.	1.6	2,039
14	FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation, 2011, 121, 4393-4408.	3.9	1,684
15	Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. New England Journal of Medicine, 2010, 362, 2155-2165.	13.9	1,444
16	Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. New England Journal of Medicine, 2003, 349, 1019-1026.	13.9	1,136
17	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.4	891
18	A New Risk Scheme to Predict Warfarin-Associated Hemorrhage. Journal of the American College of Cardiology, 2011, 58, 395-401.	1.2	754

#	Article	IF	CITATIONS
19	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2008, 133, 546S-592S.	0.4	706
20	Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2003, 290, 2685.	3.8	635
21	The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. Annals of Internal Medicine, 2009, 151, 297.	2.0	585
22	The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. Journal of the American Society of Nephrology: JASN, 2003, 14, S148-S153.	3.0	545
23	Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Annals of Internal Medicine, 1999, 131, 927.	2.0	522
24	Antithrombotic Therapy in Atrial Fibrillation. Chest, 2004, 126, 429S-456S.	0.4	519
25	Chronic Renal Insufficiency Cohort (CRIC) Study. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1302-1311.	2.2	497
26	Risk Factors for End-Stage Renal Disease. Archives of Internal Medicine, 2009, 169, 342.	4.3	486
27	Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney International, 2009, 76, 893-899.	2.6	483
28	Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. Annals of Internal Medicine, 2004, 141, 745.	2.0	463
29	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2013, 127, 224-232.	1.6	463
30	Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages. American Journal of Medicine, 2007, 120, 700-705.	0.6	457
31	Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure. Circulation, 2006, 113, 2713-2723.	1.6	455
32	Prevention of Atrial Fibrillation. Circulation, 2009, 119, 606-618.	1.6	446
33	Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation. Circulation, 2005, 112, 1687-1691.	1.6	413
34	Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. JAMA Cardiology, 2016, 1, 594.	3.0	405
35	Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation. Circulation, 2009, 119, 1363-1369.	1.6	397
36	Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). American Heart Journal, 2010, 159, 1102-1107.	1.2	386

#	Article	IF	CITATIONS
37	Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney Disease. Archives of Internal Medicine, 2005, 165, 923.	4.3	381
38	Fibroblast Growth Factor-23 and Cardiovascular Events in CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 349-360.	3.0	380
39	Nonrecovery of Kidney Function and Death after Acute on Chronic Renal Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 891-898.	2.2	350
40	Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1357-1363.	1.8	332
41	A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. Journal of the American Heart Association, 2013, 2, e000250.	1.6	315
42	Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 810-815.	1.2	308
43	Inflammation and Progression of CKD: The CRIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1546-1556.	2.2	300
44	Statin Therapy and Risks for Death and Hospitalization in Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2006, 296, 2105.	3.8	253
45	Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study. Journal of the American Geriatrics Society, 2010, 58, 338-345.	1.3	246
46	Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1725-1734.	3.0	245
47	Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International, 2005, 68, 2801-2808.	2.6	235
48	Accuracy of the Atherosclerotic Cardiovascular Risk Equation inÂaÂLargeÂContemporary, MultiethnicÂPopulation. Journal of the American College of Cardiology, 2016, 67, 2118-2130.	1.2	227
49	Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation. Circulation, 2000, 102, 11-13.	1.6	223
50	Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney International, 2010, 77, 536-542.	2.6	222
51	Age and the Risk of Warfarin-Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study. Journal of the American Geriatrics Society, 2006, 54, 1231-1236.	1.3	214
52	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. American Heart Journal, 2015, 170, 141-148.e1.	1.2	211
53	Incident Atrial Fibrillation and Risk of End-Stage Renal Disease in Adults With Chronic Kidney Disease. Circulation, 2013, 127, 569-574.	1.6	209
54	CKD and the Risk of Incident Cancer. Journal of the American Society of Nephrology: JASN, 2014, 25, 2327-2334.	3.0	207

#	Article	IF	CITATIONS
55	Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation. JAMA Cardiology, 2018, 3, 601.	3.0	194
56	Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. American Journal of Hypertension, 2010, 23, 282-289.	1.0	192
57	Epidemiology of Acute Infections among Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1487-1493.	2.2	187
58	Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 624-631.	0.9	174
59	Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 393-402.	0.9	173
60	Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Human Molecular Genetics, 2008, 17, 2320-2328.	1.4	166
61	Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin. Annals of Internal Medicine, 2001, 135, 393.	2.0	156
62	Healthy Lifestyle and Risk of Kidney Disease Progression, Atherosclerotic Events, and Death in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2015, 65, 412-424.	2.1	150
63	Physical Performance and Frailty in Chronic Kidney Disease. American Journal of Nephrology, 2013, 38, 307-315.	1.4	144
64	Race, Genetic Ancestry, and Estimating Kidney Function in CKD. New England Journal of Medicine, 2021, 385, 1750-1760.	13.9	142
65	Risks for End-Stage Renal Disease, Cardiovascular Events, and Death in Hispanic versus Non-Hispanic White Adults with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2892-2899.	3.0	140
66	The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrology, 2010, 11, 22.	0.8	139
67	Elevated BP after AKI. Journal of the American Society of Nephrology: JASN, 2016, 27, 914-923.	3.0	138
68	Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal, 2011, 162, 606-612.e1.	1.2	137
69	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clinical Infectious Diseases, 2021, 73, e4166-e4174.	2.9	135
70	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. Journal of the American College of Cardiology, 2008, 51, 865-884.	1.2	130
71	Traditional and Novel Risk Factors for Clinically Diagnosed Abdominal Aortic Aneurysm: The Kaiser Multiphasic Health Checkup Cohort Study. Annals of Epidemiology, 2007, 17, 669-678.	0.9	129
72	Epidemiology of Peripartum Cardiomyopathy. Obstetrics and Gynecology, 2011, 118, 583-591.	1.2	128

#	Article	IF	CITATIONS
73	Racial variation in the prevalence of atrial fibrillation among patients with heart failure. Journal of the American College of Cardiology, 2004, 43, 429-435.	1.2	127
74	Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 248-256.	2.2	127
75	Breast Vascular Calcification and Risk of Coronary Heart Disease, Stroke, and Heart Failure. Journal of Women's Health, 2004, 13, 381-389.	1.5	126
76	The Cardiovascular Research Network. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 138-147.	0.9	124
77	Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 333-342.	0.9	123
78	Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis. Hypertension, 2015, 65, 93-100.	1.3	122
79	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	1.2	120
80	Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology, 2014, 64, 247-252.	1.2	113
81	The Epidemiology of Atrial Fibrillation in Elderly Persons: The Tip of the Iceberg. The American Journal of Geriatric Cardiology, 2005, 14, 56-61.	0.7	107
82	CKD in Hispanics: Baseline Characteristics From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. American Journal of Kidney Diseases, 2011, 58, 214-227.	2.1	106
83	Atrial Fibrillation and Outcomes in Heart Failure With Preserved Versus Reduced Left Ventricular Ejection Fraction. Journal of the American Heart Association, 2013, 2, e005694.	1.6	105
84	ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation. Circulation, 2004, 109, 3223-3243.	1.6	101
85	Association of Spontaneous Bleeding and Myocardial Infarction With Long-Term Mortality After Percutaneous CoronaryÂIntervention. Journal of the American College of Cardiology, 2015, 65, 1411-1420.	1.2	101
86	High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 946-956.	3.0	101
87	Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017. JAMA Cardiology, 2019, 4, 1280.	3.0	101
88	Acute Kidney Injury and Risk of Heart Failure and Atherosclerotic Events. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 833-841.	2.2	99
89	Post–Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression. JAMA Internal Medicine, 2020, 180, 402.	2.6	98
90	A Longitudinal Study of Left Ventricular Function and Structure from CKD to ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 355-362.	2.2	97

#	Article	IF	CITATIONS
91	Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism. Medical Care, 2017, 55, e137-e143.	1.1	97
92	Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 297-304.	0.9	96
93	Biomarkers of inflammation and repair in kidney disease progression. Journal of Clinical Investigation, 2021, 131, .	3.9	95
94	Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection. Annals of Internal Medicine, 2009, 150, 301.	2.0	92
95	Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors forÂdeath in chronic kidney disease. Kidney International, 2017, 91, 711-719.	2.6	91
96	Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. Medical Care, 2016, 54, 365-372.	1.1	89
97	Chronic Renal Insufficiency Cohort Study (CRIC). Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2073-2083.	2.2	87
98	Arterial Stiffness, Central Pressures, and Incident Hospitalized Heart Failure in the Chronic Renal Insufficiency Cohort Study. Circulation: Heart Failure, 2014, 7, 709-716.	1.6	84
99	Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin < 10 g/dL. Kidney International, 2005, 68, 788-795.	2.6	82
100	Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. American Heart Journal, 2007, 154, 1035-1042.	1.2	82
101	Contemporary Prevalence and Correlates of Incident Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2013, 126, 393-400.	0.6	82
102	Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiology, 2016, 1, 548.	3.0	81
103	Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeutics. Pharmacoepidemiology and Drug Safety, 2001, 10, 373-377.	0.9	78
104	Statin and \hat{I}^2 -Blocker Therapy and the Initial Presentation of Coronary Heart Disease. Annals of Internal Medicine, 2006, 144, 229.	2.0	78
105	Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants. Stroke, 2012, 43, 1795-1799.	1.0	78
106	Risks and Benefits of Anticoagulation in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 461-469.	0.9	78
107	Association Between Early Recovery of Kidney Function After Acute Kidney Injury and Long-term Clinical Outcomes. JAMA Network Open, 2020, 3, e202682.	2.8	77
108	ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. Circulation, 2008, 117, 1101-1120.	1.6	76

#	Article	IF	CITATIONS
109	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Circulation, 2014, 129, 2005-2012.	1.6	73
110	A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascularÂevents, and death. Kidney International, 2021, 99, 456-465.	2.6	72
111	Geographic Variation in Cardiovascular Procedure Use Among Medicare Fee-for-Service vs Medicare Advantage Beneficiaries. JAMA - Journal of the American Medical Association, 2013, 310, 155.	3.8	71
112	Effect of Diabetes and Glycemic Control onÂlschemic Stroke Risk in AF Patients. Journal of the American College of Cardiology, 2016, 67, 239-247.	1.2	71
113	Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 49-58.	2.1	70
114	Comparative Effectiveness of Different β-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice. Archives of Internal Medicine, 2008, 168, 2415.	4.3	68
115	Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin. American Journal of Cardiology, 2014, 114, 583-586.	0.7	68
116	Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2021, 77, 235-244.	2.1	68
117	Chronic Kidney Disease and Risk for Presenting With Acute Myocardial Infarction Versus Stable Exertional Angina in Adults With Coronary Heart Disease. Journal of the American College of Cardiology, 2011, 58, 1600-1607.	1.2	66
118	Patterns of Comorbidity in Older Adults with Heart Failure: The Cardiovascular Research Network <scp>PRESERVE</scp> Study. Journal of the American Geriatrics Society, 2013, 61, 26-33.	1.3	66
119	Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 525-533.	0.9	66
120	Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrology, 2018, 19, 146.	0.8	65
121	Burden and Outcomes of HeartÂFailureÂHospitalizations in AdultsÂWith Chronic Kidney Disease. Journal of the American College of Cardiology, 2019, 73, 2691-2700.	1.2	65
122	Trends in Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN). American Journal of Medicine, 2017, 130, 317-327.	0.6	64
123	Statins for Primary Prevention in Older Adults. JAMA - Journal of the American Medical Association, 2016, 316, 1971.	3.8	63
124	Risk factors for progression of coronary artery calcification in patients with chronic kidney disease: The CRIC study. Atherosclerosis, 2018, 271, 53-60.	0.4	63
125	Use of Medications for Secondary Prevention After Coronary Bypass Surgery Compared With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2013, 61, 295-301.	1.2	62
126	Comparative Effectiveness of Multivessel Coronary Bypass Surgery and Multivessel Percutaneous Coronary Intervention. Annals of Internal Medicine, 2013, 158, 727.	2.0	62

# ARTICLE		IF	CITATIONS
	s accurately identify individuals with clinically significant atherosclerotic gical Genomics, 2007, 31, 402-409.	1.0	60
	on and Risk of Death in Adults With Chronic Kidney Disease. Journal of the ation, 2014, 3, e001303.	1.6	60
Visit-to-visit variability events in patients with	of blood pressure and death, end-stage renal disease, and cardiovascular chronic kidney disease. Journal of Hypertension, 2016, 34, 244-252.	0.3	60
Gender and risk of adv 130 1147-1152.	erse outcomes in heart failure. American Journal of Cardiology, 2004, 94,	0.7	59
Longitudinal Weight C 131 American Journal of Kic	hange During CKD Progression and Its Association With Subsequent Mortality. dney Diseases, 2018, 71, 657-665.	2.1	59
Matrix metalloproteina 132 myocardial infarction a 1043-1051.	ase circulating levels, genetic polymorphisms, and susceptibility to acute among patients with coronary artery disease. American Heart Journal, 2007, 154,	1.2	58
Urine Neutrophil Gelat 133 Results From the Chro Diseases, 2015, 65, 26	inase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: nic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney 57-274.	2.1	58
	opensity and Coronary Artery Calcification Among Patients With CKD: The CRIC iency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	2.1	58
	Chronic Kidney Disease Progression and Cardiovascular Disease: Results from can Journal of Nephrology, 2014, 40, 399-407.	1.4	56
136 Common polymorphisi 2008, 123, 399-408.	ms of ALOX5 and ALOX5AP and risk of coronary artery disease. Human Genetics,	1.8	54
	of potentially high-risk arrhythmias detected through long term continuous diographic monitoring. BMC Cardiovascular Disorders, 2016, 16, 35.	0.7	54
	markers and Risks of Cardiovascular Disease Events and All-Cause Death: The urnal of the American Society of Nephrology: CJASN, 2017, 12, 761-771.	2.2	53
139 Mild prolonged chronic 139 Transplantation, 2016,	c hyponatremia and risk of hip fracture in the elderly. Nephrology Dialysis , 31, 1662-1669.	0.4	52
	s in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. dney Diseases, 2017, 70, 337-346.	2.1	52
	ta network for cardiovascular disease: the CVRN. Expert Review of y, 2008, 6, 1043-1045.	0.6	50
	ety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral tions in the Treatment of Symptomatic Peripheral Arterial Disease. Circulation, 	1.6	50
	lant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic American Geriatrics Society, 2017, 65, 241-248.	1.3	48

Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

#	Article	IF	CITATIONS
145	Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 559-569.	3.0	47
146	Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis. Hypertension, 2017, 70, 435-443.	1.3	47
147	Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrology, 2016, 17, 13.	0.8	46
148	Inflammation and Arterial Stiffness in Chronic Kidney Disease: Findings From the CRIC Study. American Journal of Hypertension, 2017, 30, 400-408.	1.0	46
149	Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. American Heart Journal, 2007, 154, 1052-1058.	1.2	45
150	A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis, 2008, 198, 136-144.	0.4	44
151	Candidate Gene Association Study of Coronary Artery Calcification in Chronic Kidney Disease. Journal of the American College of Cardiology, 2013, 62, 789-798.	1.2	44
152	Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1971-1978.	1.1	44
153	Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology, 2014, 82, 1033-1037.	1.5	43
154	Challenges of Ascertaining National Trends in the Incidence of Coronary Heart Disease in the United States. Journal of the American Heart Association, 2014, 3, e001097.	1.6	43
155	Cognitive Impairment in Non–Dialysis-Dependent CKD and the Transition to Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2018, 72, 499-508.	2.1	43
156	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. American Journal of Kidney Diseases, 2019, 73, 827-836.	2.1	43
157	Central Pulse Pressure in Chronic Kidney Disease. Hypertension, 2010, 56, 518-524.	1.3	42
158	Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort. American Journal of Kidney Diseases, 2019, 73, 163-173.	2.1	42
159	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
160	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. European Heart Journal, 2014, 35, 2115-2122.	1.0	41
161	Effect of Race/Ethnicity on the Efficacy of Warfarin. CNS Drugs, 2008, 22, 815-825.	2.7	40
162	Predicting Renal Recovery After Dialysis-Requiring Acute Kidney Injury. Kidney International Reports, 2019, 4, 571-581.	0.4	40

#	Article	IF	CITATIONS
163	Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 26-34.	2.2	40
164	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. Circulation, 2020, 141, 1915-1926.	1.6	40
165	Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100Âmg/dl. American Journal of Cardiology, 2015, 116, 1700-1704.	0.7	39
166	Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Internal Medicine, 2018, 178, 390.	2.6	39
167	Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 60-68.	2.2	38
168	Plasma Leptin Levels and Coronary Artery Calcification in Older Adults. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 729-732.	1.8	37
169	Risk Factors for Coronary Artery Calcium Among Patients With Chronic Kidney Disease (from the) Tj ETQq1 1 0.7	784314 rg 0.7	gBT /Overlock
170	Acute Kidney Injury After CABG Versus PCI. Journal of the American College of Cardiology, 2014, 64, 985-994.	1.2	37
171	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. Annals of Internal Medicine, 2017, 167, 845.	2.0	37
172	Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006212.	0.9	37
173	Comparative Effectiveness of Beta-Adrenergic Antagonists (Atenolol, Metoprolol Tartrate,) Tj ETQq1 1 0.784314 Cardiology, 2007, 100, 690-696.	rgBT /Ov 0.7	erlock 10 Tf 5 36
174	Susceptibility Loci for Clinical Coronary Artery Disease and Subclinical Coronary Atherosclerosis Throughout the Life-Course. Circulation: Cardiovascular Genetics, 2015, 8, 803-811.	5.1	36
175	Serum Calcification Propensity and Clinical Events in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1562-1571.	2.2	36
176	Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study. American Journal of Kidney Diseases, 2018, 72, 390-399.	2.1	34
177	Report of the National Heart, Lung, and Blood Institute Working Group. Circulation, 2016, 133, 1410-1418.	1.6	33
178	GFR, Body Mass Index, and Low High-Density Lipoprotein Concentration in Adults With and Without CKD. American Journal of Kidney Diseases, 2007, 50, 552-558.	2.1	32
179	Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. American Heart Journal, 2013, 165, 800-808.e2.	1.2	32
180	Cardiovascular Disease Consequences of CKD. Seminars in Nephrology, 2016, 36, 293-304.	0.6	32

#	Article	IF	CITATIONS
181	Comparative Trends in Heart Disease, Stroke, and All-Cause Mortality in the United States and a Large Integrated Healthcare Delivery System. American Journal of Medicine, 2018, 131, 829-836.e1.	0.6	32
182	Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014415.	1.6	32
183	Risk Factors for Adverse Outcomes by Left Ventricular Ejection Fraction in a Contemporary Heart Failure Population. Circulation: Heart Failure, 2013, 6, 635-646.	1.6	31
184	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. JACC: Heart Failure, 2013, 1, 445-453.	1.9	30
185	Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. BMC Medical Genetics, 2008, 9, 23.	2.1	29
186	Metabolic Syndrome, Components, and Cardiovascular Disease Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Nephrology, 2011, 33, 477-484.	1.4	29
187	Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: a cross-sectional study. BMC Nephrology, 2015, 16, 211.	0.8	29
188	Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic) Tj ETQq0 0 0 545-553.	rgBT /Ov 2.1	erlock 10 Tf 29
189	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	29
190	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. Journal of the American Heart Association, 2018, 7, .	1.6	29
191	Age, sex, and racial influences on the Beckman Coulter AccuTnI+3 99th percentile. Clinica Chimica Acta, 2015, 444, 149-153.	0.5	28
192	Impact of AKI on Urinary Protein Excretion: Analysis of Two Prospective Cohorts. Journal of the American Society of Nephrology: JASN, 2019, 30, 1271-1281.	3.0	28
193	Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 2249-2257.	1.2	27
194	Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2018, 121, 602-608.	0.7	27
195	Acute Kidney Injury and Risk of CKD and Hypertension after Pediatric Cardiac Surgery. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1403-1412.	2.2	27
196	Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 2303-2314.	3.0	27
197	Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Journal of Thrombosis and Thrombolysis, 2003, 15, 41-46.	1.0	25
198	Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease. PPAR Research, 2009, 2009, 1-11.	1.1	25

#	Article	IF	CITATIONS
199	Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation. Circulation, 2020, 141, 482-492.	1.6	25
200	Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease. Current Opinion in Nephrology and Hypertension, 2006, 15, 296-302.	1.0	24
201	Intersection of cardiovascular disease and kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 275-282.	1.0	24
202	Age and Sex Differences in Longâ€Term Outcomes Following Implantable Cardioverterâ€Defibrillator Placement in Contemporary Clinical Practice: Findings From the Cardiovascular Research Network. Journal of the American Heart Association, 2015, 4, e002005.	1.6	23
203	Contemporary Burden and Correlates of Symptomatic Paroxysmal Supraventricular Tachycardia. Journal of the American Heart Association, 2018, 7, .	1.6	23
204	Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study. American Journal of Kidney Diseases, 2021, 78, 200-209.e1.	2.1	23
205	Cardiovascular Disease Among Hispanics and Non-Hispanics in the Chronic Renal Insufficiency Cohort (CRIC) Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2121-2131.	2.2	22
206	Longitudinal Study of Implantable Cardioverter-Defibrillators. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, e78-85.	0.9	22
207	Hospital-Level Variation in Use of Cardiovascular Testing for Adults WithÂlncident Heart Failure. JACC: Cardiovascular Imaging, 2014, 7, 690-700.	2.3	22
208	Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure. Circulation: Heart Failure, 2015, 8, 702-708.	1.6	22
209	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney International, 2016, 90, 1348-1356.	2.6	22
210	High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. Heart, 2016, 102, 1177-1182.	1.2	22
211	Trends Associated With Large-scale Expansion of Peritoneal Dialysis Within an Integrated Care Delivery Model. JAMA Internal Medicine, 2019, 179, 1537.	2.6	22
212	Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 394-403.	2.1	22
213	Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. American Heart Journal, 2007, 154, 1059-1064.	1.2	21
214	Pre-admission proteinuria impacts risk of non-recovery after dialysis-requiring acute kidneyÂinjury. Kidney International, 2018, 93, 968-976.	2.6	21
215	Multimorbidity Burden and Adverse Outcomes in a Communityâ€Based Cohort of Adults with Heart Failure. Journal of the American Geriatrics Society, 2018, 66, 2305-2313.	1.3	21
216	Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study. BMC Nephrology, 2018, 19, 134.	0.8	21

#	Article	IF	CITATIONS
217	A Natural Language Processing–Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Network Open, 2021, 4, e2135152.	2.8	21
218	Coronary artery bypass grafting and percutaneous coronary intervention in patients with end-stage renal disease. European Journal of Cardio-thoracic Surgery, 2015, 47, e193-e198.	0.6	20
219	Right coronary wall cmr in the older asymptomatic advance cohort: positive remodeling and associations with type 2 diabetes and coronary calcium. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 75.	1.6	19
220	Stability of Highâ€Quality Warfarin Anticoagulation in a Communityâ€Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Journal of the American Heart Association, 2016, 5, .	1.6	19
221	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. Annals of Internal Medicine, 2018, 169, 517.	2.0	19
222	Contemporary Reevaluation of Race and Ethnicity With Outcomes in Heart Failure. Journal of the American Heart Association, 2021, 10, e016601.	1.6	19
223	Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 77, 907-919.	2.1	19
224	Ethnic Differences in Coronary Artery Calcium in a Healthy Cohort Aged 60 to 69 Years. American Journal of Cardiology, 2007, 100, 981-985.	0.7	18
225	Statin use and risk of basal cell carcinoma. Journal of the American Academy of Dermatology, 2009, 61, 66-72.	0.6	18
226	Physical Activity in Older Subjects Is Associated With Increased Coronary Vasodilation. JACC: Cardiovascular Imaging, 2011, 4, 622-629.	2.3	18
227	Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thrombosis Research, 2015, 136, 1160-1164.	0.8	18
228	Storage Time and Urine Biomarker Levels in the ASSESS-AKI Study. PLoS ONE, 2016, 11, e0164832.	1.1	18
229	Cardiac Biomarkers and Risk of Mortality in CKD (the CRIC Study). Kidney International Reports, 2020, 5, 2002-2012.	0.4	18
230	COVID-19 and Risk of VTE in Ethnically Diverse Populations. Chest, 2021, 160, 1459-1470.	0.4	18
231	Analysis of Worsening HeartÂFailure Events in an Integrated Health CareÂSystem. Journal of the American College of Cardiology, 2022, 80, 111-122.	1.2	18
232	Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Medicine, 2011, 9, 78.	2.3	17
233	Comparison of Medication Practices in Patients With Heart Failure and Preserved Versus Those With Reduced Ejection Fraction (from the Cardiovascular Research Network [CVRN]). American Journal of Cardiology, 2013, 111, 1324-1329.	0.7	17
234	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	17

#	Article	IF	CITATIONS
235	Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study. Kidney International Reports, 2019, 4, 80-93.	0.4	17
236	Short-Term Outcomes and Factors Associated With Adverse Events Among Adults Discharged From the Emergency Department After Treatment for Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	16
237	Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. Journal of the American Society of Nephrology: JASN, 2022, 33, 613-627.	3.0	16
238	Effectiveness and Safety of Spironolactone for Systolic Heart Failure. American Journal of Cardiology, 2013, 112, 1427-1432.	0.7	15
239	Sex differences in cardiovascular outcomes in patients with incident hypertension. Journal of Hypertension, 2013, 31, 271-277.	0.3	15
240	Comparison of Frequency and Outcome of Major Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation on Versus Not Receiving Warfarin Therapy (from the ATRIA and ATRIA-CVRN Cohorts). American Journal of Cardiology, 2015, 115, 40-46.	0.7	15
241	The Heart Failure Readmission Intervention by Variable Early Follow-up (THRIVE) Study. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006553.	0.9	15
242	Community-Based Epidemiology of Hospitalized Acute Kidney Injury. Pediatrics, 2020, 146, .	1.0	15
243	Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study. Thrombosis Research, 2020, 189, 112-118.	0.8	15
244	Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 26-36.	2.2	15
245	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 383-392.	2.1	15
246	Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study. BMC Nephrology, 2011, 12, 44.	0.8	14
247	The Complex Relationship of Race to Outcomes in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2015, 128, 591-600.	0.6	14
248	Acute Kidney Injury Ascertainment Is Affected by the Use of First Inpatient Versus Outpatient Baseline Serum Creatinine. Kidney International Reports, 2018, 3, 211-215.	0.4	14
249	Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. American Journal of Hypertension, 2017, 30, 822-829.	1.0	13
250	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. Journal of the American Geriatrics Society, 2017, 65, 35-41.	1.3	13
251	Long-Term Outcomes of Adults With Heart Failure by Left Ventricular Systolic Function Status. American Journal of Cardiology, 2018, 122, 1008-1016.	0.7	13
252	How much can we trust electronic health record data?. Healthcare, 2020, 8, 100444.	0.6	13

#	Article	IF	CITATIONS
253	Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. BMC Endocrine Disorders, 2020, 20, 25.	0.9	13
254	A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. International Journal of Cardiology, 2020, 309, 95-99.	0.8	13
255	Community-Based Trends in Acute Myocardial Infarction From 2008 to 2014. Journal of the American College of Cardiology, 2016, 68, 666-668.	1.2	12
256	Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverterâ€Defibrillators in the Cardiovascular Research Network. Journal of the American Heart Association, 2018, 7, .	1.6	12
257	Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. American Journal of Medicine, 2019, 132, 1450-1457.e1.	0.6	12
258	Research-based versus clinical serum creatinine measurements and the association of acute kidney injury with subsequent kidney function: findings from the Chronic Renal Insufficiency Cohort study. CKJ: Clinical Kidney Journal, 2020, 13, 55-62.	1.4	12
259	Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. Journal of the American Heart Association, 2021, 10, e020377.	1.6	12
260	Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation. Progress in Cardiovascular Diseases, 2005, 48, 108-124.	1.6	11
261	Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal of Cardiac Failure, 2013, 19, 176-182.	0.7	11
262	Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 361-369.	1.8	11
263	Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2021, 52, 1101-1109.	1.0	11
264	Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). American Heart Journal, 2021, 235, 54-64.	1.2	11
265	Ethnic differences in the development of albuminuria: the DISTANCE study. American Journal of Managed Care, 2011, 17, 737-45.	0.8	11
266	Anticoagulation in atrial fibrillation: impact of mental illness. American Journal of Managed Care, 2015, 21, e609-17.	0.8	11
267	Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention. American Heart Journal, 2015, 169, 149-154.	1.2	10
268	Measurement Error as Alternative Explanation for the Observation that CrCl/GFR Ratio is Higher at Lower GFR. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1574-1581.	2.2	10
269	Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study. American Heart Journal, 2017, 194, 25-38.	1.2	10
270	Implication of Trends in Timing of Dialysis Initiation for Incidence of End-stage Kidney Disease. JAMA Internal Medicine, 2020, 180, 1647.	2.6	10

#	Article	IF	CITATIONS
271	Meta-Analysis of 26 638 Individuals Identifies Two Genetic Loci Associated With Left Ventricular Ejection Fraction. Circulation Genomic and Precision Medicine, 2020, 13, e002804.	1.6	10
272	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. American Journal of Cardiology, 2016, 118, 697-699.	0.7	9
273	Early Pregnancy Blood Pressure Patterns Identify Risk of Hypertensive Disorders of Pregnancy Among Racial and Ethnic Groups. Hypertension, 2022, 79, 599-613.	1.3	9
274	Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study. Mayo Clinic Proceedings, 2022, 97, 465-479.	1.4	9
275	Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. Thrombosis Research, 2016, 137, 97-102.	0.8	8
276	Effectiveness of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With End-Stage Renal Disease. American Journal of Cardiology, 2016, 117, 1596-1603.	0.7	8
277	Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. Journal of the American Geriatrics Society, 2017, 65, 2610-2618.	1.3	8
278	Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study. American Journal of Medicine, 2015, 128, 1252.e1-1252.e11.	0.6	7
279	Kidney function, proteinuria and breast arterial calcification in women without clinical cardiovascular disease: The MINERVA study. PLoS ONE, 2019, 14, e0210973.	1.1	7
280	Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1015-1024.	2.2	7
281	Association Between Kidney Clearance of Secretory Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 78, 226-235.e1.	2.1	7
282	Temporal Trends in Mortality after Coronary Artery Revascularization in Patients with End-Stage Renal Disease. , 2014, 18, 11-16.		7
283	Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD. Kidney International Reports, 2021, 6, 1592-1602.	0.4	6
284	Time-Updated Changes in Estimated GFR and Proteinuria and Major Adverse Cardiac Events: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2022, 79, 36-44.e1.	2.1	6
285	A Marginal Structural Modeling Approach with Super Learning for a Study on Oral Bisphosphonate Therapy and Atrial Fibrillation. Journal of Causal Inference, 2013, 1, 21-50.	0.5	6
286	Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study. BMJ Open, 2022, 12, e048755.	0.8	6
287	Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD. Kidney360, 2022, 3, 859-871.	0.9	6
288	Stroke prevention in atrial fibrillation: another step sideways. Lancet, The, 2008, 371, 278-280.	6.3	5

#	Article	IF	CITATIONS
289	Incremental prognostic information from kidney function in patients with new onset coronary heart disease. American Heart Journal, 2014, 167, 86-92.	1.2	5
290	Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverterâ€Defibrillator Therapies. Journal of the American Geriatrics Society, 2019, 67, 1370-1378.	1.3	5
291	Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. American Journal of Cardiology, 2020, 125, 553-561.	0.7	5
292	Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006415.	0.9	5
293	Cardiovascular disease history and β-blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies. Hypertension Research, 2021, 44, 700-710.	1.5	5
294	Change in ankle–brachial index and mortality among individuals with chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort Study. Nephrology Dialysis Transplantation, 2021, 36, 2224-2231.	0.4	5
295	Prediction of Incident Heart Failure in CKD: The CRIC Study. Kidney International Reports, 2022, 7, 708-719.	0.4	5
296	Prognostic Accuracy of Presepsis and Intrasepsis Characteristics for Prediction of Cardiovascular Events After a Sepsis Hospitalization. , 2022, 4, e0674.		5
297	Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury. Kidney International Reports, 2022, 7, 1502-1513.	0.4	5
298	Prognostic value of echocardiography for heart failure and death in adults with chronic kidney disease. American Heart Journal, 2022, 248, 84-96.	1.2	5
299	Framingham and American College of Cardiology/American Heart Association Pooled Cohort Equations, Highâ€Sensitivity Troponin T, and Nâ€Terminal Pro–Brainâ€Type Natriuretic Peptide for Predicting Atherosclerotic Cardiovascular Events Across the Spectrum of Kidney Dysfunction. Journal of the American Heart Association, 2022, 11, .	1.6	5
300	Statin Therapy and Risk of Incident Diabetes Mellitus in Adults With Cardiovascular Risk Factors. American Journal of Cardiology, 2020, 125, 534-541.	0.7	4
301	Vitamin K Status and Cognitive Function in Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. Current Developments in Nutrition, 2022, 6, nzac111.	0.1	4
302	Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 663-670.	0.9	3
303	Association of Age to Mortality and Repeat Revascularization in End-Stage Renal Disease Patients: Implications for Clinicians and Future Health Policies. , 2016, 20, 4-9.		3
304	Multimorbidity is strongly associated with long-term but not short-term mortality after cardiac valve replacement. International Journal of Cardiology, 2016, 215, 417-421.	0.8	3
305	Body mass index and chronic kidney disease outcomes after acute kidney injury: a prospective matched cohort study. BMC Nephrology, 2021, 22, 200.	0.8	3
306	Achieved blood pressure post-acute kidney injury and risk of adverse outcomes after AKI: A prospective parallel cohort study. BMC Nephrology, 2021, 22, 270.	0.8	3

#	Article	IF	CITATIONS
307	Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study. PLoS ONE, 2021, 16, e0257674.	1.1	3
308	Diagnostic Yield, Outcomes, and Resource Utilization With Different Ambulatory Electrocardiographic Monitoring Strategies. American Journal of Cardiology, 2022, 166, 38-44.	0.7	3
309	Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD. Journal of the American Society of Nephrology: JASN, 2022, 33, 442-453.	3.0	3
310	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. American Heart Journal, 2022, 249, 76-76.	1.2	3
311	Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism. Thrombosis Research, 2022, 216, 97-102.	0.8	3
312	The Association of Gender to Cardiovascular Outcomes After Coronary Artery Revascularization in Patients With Endâ€6tage Renal Disease. Clinical Cardiology, 2014, 37, 546-551.	0.7	2
313	Getting it Straight: Avoiding Blunders While Criticizing a Peer's Work. International Journal of Epidemiology, 2016, 45, 619-620.	0.9	2
314	Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. Heart, 2017, 103, 529-537.	1.2	2
315	Noncardiac-Related Morbidity, Mobility Limitation, and Outcomes in Older Adults With Heart Failure. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1981-1988.	1.7	2
316	Timing of AKI after urgent percutaneous coronary intervention and clinical outcomes: a high-dimensional propensity score analysis. BMC Nephrology, 2021, 22, 300.	0.8	2
317	Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVIDâ€19 pandemic. Clinical Cardiology, 2022, , .	0.7	2
318	Deoxycholic Acid and Coronary Artery Calcification in the Chronic Renal Insufficiency Cohort. Journal of the American Heart Association, 2022, 11, e022891.	1.6	2
319	Multimorbidity Burden and Incident Heart Failure Among People With and Without HIV: The HIV-HEART Study. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 218-227.	1.2	2
320	Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: The ADVANCE study. Clinical Trials and Regulatory Science in Cardiology, 2015, 5, 1-7.	1.0	1
321	Atrial Fibrillation and Longitudinal Change in Cognitive Function in CKD. Kidney International Reports, 2021, 6, 669-674.	0.4	1
322	Dialysis therapy and mortality in older adults with heart failure and advanced chronic kidney disease: A high-dimensional propensity-matched cohort study. PLoS ONE, 2022, 17, e0262706.	1.1	1
323	Human immunodeficiency virus infection and risks of morbidity and death in adults with incident heart failure. European Heart Journal Open, 2021, 1, .	0.9	1
324	Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 226-227.	3.3	0

#	Article	IF	CITATIONS
325	Response to Letter Regarding Article, "Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study― Circulation, 2007, 115, .	1.6	Ο
326	Response to Letter Regarding Article, "Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Studyâ€: Circulation, 2009, 120, .	1.6	0
327	Response to Letter Regarding Article, "Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation: Insights From the HMO Research Network-Stent Registry (HMORN-Stent)â€: Circulation: Cardiovascular Interventions, 2010, 3, .	1.4	0
328	Timing of Dialysis Initiation and End-Stage Kidney Disease Incidence—Reply. JAMA Internal Medicine, 2021, 181, 725.	2.6	0
329	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130, .	1.6	Ο